ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1077

The Economic Burden of CKD Progression Among Patients with and Without Major Adverse Cardiac Events (MACE) in the US

Session Information

Category: CKD (Non-Dialysis)

  • 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Okoro, Tony, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Chen, Yong, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Casillas, Linda, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Zheng, Shan, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Parks, Daniel C., GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States

Little is known about the costs of CKD progression among patients with cardiovascular disease. The objective of this study was to assess the economic burden of CKD progression among CKD patients with and without MACE.


Optum claims data were used to identify patients with baseline non-dialysis dependent CKD (stages 3a, 3b, 4 and 5) in 2013 using estimated glomerular filtration rate (eGFR) based on the Kidney Disease Outcomes Quality Initiative (KDOQI) diagnosis criteria. Patients were followed through 6/30/2017 to assess CKD progression defined as worsening CKD stage from baseline. Annualized all-cause costs were assessed between patients with and without defined CKD stage progression and then stratified by the presence or absence of follow-up MACE.


57,597 CKD patients were identified in 2013, among which 35,975, 16,982, 4,340 and 299 had CKD stages 3a, 3b, 4 and 5, respectively. Among those without MACE (n=47,004), mean annualized all-cause costs increased from stage 3a ($8,398) to 5 ($12,711) in those without stage progression and from stage3a ($12,062) to 5 ($79,093) in those with stage progression. Mean annualized all-cause costs among patients with ≥1 MACE (n=10,593) were from $35,924 for stage3a to $42,479 for stage5 without stage progression and from $40,687 (stage 3a) to $97,013 (stage 5) with stage progression. Overall, CKD progression costs for the entire cohort increased from stage3a ($6,010) to stage5 ($66,737) (P for trend < 0.001). The trends were consistent among those with and without MACE.


Progression of CKD increases the economic burden in patients regardless of MACE status but healthcare costs are higher in those with MACE compared to those without MACE. Preventing renal function decline could reduce economic burden seen in patients with advanced CKD stages and MACE.


  • Commercial Support